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Background—The role of the nitric oxide/cGMP/cGMP–dependent protein kinase G pathway in myocardial protection
and preconditioning has been the object of intensive investigations. The novel soluble guanylate cyclase activator
cinaciguat has been reported to elevate intracellular [cGMP] and activate the nitric oxide/cGMP/cGMP–dependent
protein kinase G pathway in vivo. We investigated the effects of cinaciguat on myocardial infarction induced by
isoproterenol in rats.
Methods and Results—Rats were treated orally twice a day for 4 days with vehicle or cinaciguat (10 mg/kg). Isoproterenol
(85 mg/kg) was injected subcutaneously 2 days after the first treatment at an interval of 24 hours for 2 days to produce
myocardial infarction. After 17 hours, histopathological observations and left ventricular pressure-volume analysis to
assess cardiac function with a Millar microtip pressure-volume conductance catheter were performed, and levels of
biochemicals of the heart tissues were measured. Gene expression analysis was performed by quantitative real-time
polymerase chain reaction. Isolated canine coronary arterial rings exposed to peroxynitrite were investigated for
vasomotor function, and immunohistochemistry was performed for cGMP and nitrotyrosine. The present results show
that cinaciguat treatment improves histopathological lesions, improves cardiac performance, improves impaired cardiac
relaxation, reduces oxidative stress, ameliorates intracellular enzyme release, and decreases cyclooxygenase 2,
transforming growth factor-, and -actin mRNA expression in experimentally induced myocardial infarction in rats.
In vitro exposure of coronary arteries to peroxynitrite resulted in an impairment of endothelium-dependent vasorelax-
ation, increased nitro-oxidative stress, and reduced intracellular cGMP levels, which were all improved by cinaciguat.
A cardioprotective effect of postischemic cinaciguat treatment was shown in a canine model of global
ischemia/reperfusion.
Conclusion—Pharmacological soluble guanylate cyclase activation could be a novel approach for the prevention and
treatment of ischemic heart disease. (Circulation. 2009;120:677-686.)
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Myocardial infarction (MI) is the rapid development ofmyocardial necrosis that occurs when a coronary artery
is severely blocked so that there is a significant imbalance
between the oxygen supply and the demand of the myocar-
dium, causing damage or death of a portion of the myocar-
dium. A better understanding of the processes involved in
myocardial injury has stimulated the search for new drugs
that could limit the myocardial damage. It has been proposed
that the nitric oxide (NO)/soluble guanylate cyclase (sGC)/
cGMP/cGMP–dependent protein kinase G pathway may play
a pivotal role in myocardial protection and preconditioning.
In the healthy endothelium, vascular NO binds to the ferrous
heme iron (Fe2) and activates a key signal transduction
enzyme, sGC, resulting in cGMP generation. This activation
promotes various actions such as vasodilation, inhibition of
platelet aggregation, and growth inhibition.1 Cardiovascular
disease is frequently associated with impaired NO/sGC/
cGMP signaling. The concept has been advanced that under
physiological conditions sGC exists as a pool of oxidized (or
heme-free) NO-insensitive sGC and reduced NO-sensitive
sGC and that this NO-insensitive sGC pool is increased under
pathophysiological conditions.2 Organic nitrates act as a
source of NO, but their efficacy is limited by the development
of tolerance after sustained administration,3 the absence of
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clinically relevant antiplatelet activity,4 and the inability to
activate NO-insensitive sGC. Therefore, compounds that
activate NO-insensitive sGC with a profile of activity similar
to that of organic nitrates but devoid of the problem of
tolerance and the potential cytotoxic actions of NO may offer
a new approach for treating cardiovascular disease. A novel
sGC activator, cinaciguat (BAY 58–2667), which activates
sGC in its NO-insensitive, oxidized (or heme-deficient) state,
induces cGMP generation and vasodilation preferentially in
diseased vessels.5 Cinaciguat exhibits a potent vasorelaxant
effect on isolated vessels, in vitro and in vivo antiplatelet
activity, a strong blood pressure–lowering effect, and a
hemodynamic profile comparable to that of organic nitrates.6
Its pharmacokinetic and pharmacodynamic properties, toler-
ability, and safety have recently been assessed by phase I
clinical trials.7 A phase IIb clinical study for the indication of
acute decompensated heart failure is currently underway.8
Clinical Perspective on p 686
Isoproterenol, a synthetic catecholamine and -adrenergic
agonist, has been found to induce MI in rats,9 and the acute
phases of myocardial necrosis and repair mimic those that
occur in patients: changes in serum enzymes,10 ECG alter-
ations,11 and histological changes.12 The rat model of
isoproterenol-induced MI offers a standardized noninvasive
technique for studying the effects of various cardioprotective
therapeutic attempts.
In the present study, the effects of cinaciguat in
isoproterenol-induced MI in rats were evaluated. We focus on
the correlated histopathological, biochemical, and functional
changes and on cardiac performance-related gene expression.
In the pathogenesis of isoproterenol-induced MI, it has been
proposed that reactive oxygen-derived free radicals play a
crucial role.13 The secondary aim of our experiment was to
examine the effects of cinaciguat on vascular dysfunction
induced by nitro-oxidative stress on isolated canine coronary
arterial rings. Additionally, a clinically relevant canine model
of global reversible cardiac ischemia/reperfusion injury was
used to evaluate the effects of a postischemic treatment
protocol with cinaciguat.
Methods
Animals
Male Sprague-Dawley rats (250 to 350 g; Charles River, Sulzfeld,
Germany) and foxhound dogs of both sexes were used in these
experiments. Rats were housed in a room at a constant temperature
of 222°C with 12-hour light/dark cycles and were fed a standard
laboratory rat diet and water ad libitum. The rats were acclimatized
for at least 1 week before experiments and were randomly assigned
to different groups. All animals received humane care in compliance
with the Principles of Laboratory Animal Care formulated by the
National Society for Medical Research and the Guide for the Care
and Use of Laboratory Animals prepared by the Institute of Labo-
ratory Animal Resources and published by the National Institutes of
Health (NIH Publication No. 86–23, revised 1996). The experiments
were approved by the ethics committee of the Land Baden-
Württemberg for Animal Experimentation.
Rat Model of Isoproterenol-Induced MI
Induction of Myocardial Injury
Isoproterenol was injected subcutaneously into rats (85 mg/kg) daily
for 2 consecutive days to induce MI,14 and the mortality rate of rats
(within 30 minutes and between 30 minutes and 24 hours) in
different dosage groups was assessed.
Experimental Groups
Rats were randomly divided into 5 groups. The control group
received methylcellulose for 4 days and sterile distilled water on
days 3 and 4. The isoproterenol-group received methylcellulose for
4 days and isoproterenol on days 3 and 4. The cinaciguat plus
isoproterenol group received cinaciguat for 4 days and isoproterenol
on days 3 and 4. The cinaciguat group rats received cinaciguat for 4
days and sterile distilled water on days 3 and 4. The isoproterenol
plus cinaciguat group received cinaciguat 12 hours after the first
isoproterenol injection and at the same time as the second injection
of isoproterenol. The experiment was stopped 17 to 22 hours after
the last administration of drugs.
Hemodynamic Measurements
Left ventricular (LV) pressure-volume (PV) analysis to assess
cardiac function with a Millar (Houston, Tex) microtip PV-
conductance catheter was performed as described previously15 (see
the online-only Data Supplement).
Canine Model of Global Reversible Myocardial
Ischemia/Reperfusion
General Management and Surgical Procedure
Anesthetized dogs underwent global cardiac ischemia/reperfusion in
the setting of cardiopulmonary bypass with hypothermic cardiac
arrest. After initiation of cardiopulmonary bypass, the ascending
aorta was cross-clamped, and the hearts were arrested with crystal-
loid cardioplegia (Custodiol). After 60 minutes, the aortic cross-
clamp was released, and the reperfusion phase was initiated. Each
animal underwent 60 minutes of cardiac ischemia and 60 minutes of
reperfusion16 (see the online-only Data Supplement).
Experimental Groups
Two groups of dogs were studied. The control group (n6) received
placebo; the cinaciguat group (n6) received cinaciguat in a dose of
12.5 g in a short infusion for 10 minutes starting 5 minutes before
the initiation of reperfusion.
Hemodynamic Measurements
Heart rate (HR), mean arterial pressure (MAP), cardiac output,
coronary blood flow, and PV loop–derived (conductance catheter)
contractility indexes were assessed at baseline and at 60 minutes of
reperfusion16 (see the online-only Data Supplement).
In Vitro Model of Vascular Nitro-Oxidative Stress
Preparation of Isolated Canine Coronary Arterial Rings
Hearts were excised from anesthetized healthy control dogs, and the
coronary arteries were isolated and placed in cold (4°C) Krebs-
Henseleit solution (118 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L
KH2PO4, 1.2 mmol/L MgSO4, 1.77 mmol/L CaCl2, 25 mmol/L
NaHCO3, and 11.4 mmol/L glucose; pH7.4). After dissection of
surrounding tissue, segments (length, 4 mm) of coronary arteries
were placed in 30 mL Krebs-Henseleit solution supplemented with
10 mmol/L HEPES buffer, incubated for 20 minutes with vehicle or
cinaciguat (109 mol/L), and then exposed to vehicle or peroxynitrite
(150 mol/L) to induce endothelial injury
Experimental Groups, Measurement Protocol
The experimental groups were as follows: control group (vehicle
treatment, exposure to vehicle), peroxynitrite group (vehicle treat-
ment, exposure to peroxynitrite), cinaciguat plus peroxynitrite group
(cinaciguat treatment, exposure to peroxynitrite), and cinaciguat
group (cinaciguat treatment, exposure to vehicle). After the incuba-
tion time, a vessel ring from each group was used for functional
isometric tension measurements as described previously.17 Coronary
preparations were preconstricted with U46619 (5107 mol/L), and
relaxation responses were examined by the addition of cumulative
concentrations of acetylcholine (109 to 5105 mol/L). For testing
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relaxing responses of smooth muscle cells, sodium nitroprusside
(1010 to 104 mol/L) was used. Relaxation is expressed as percent of
contraction induced by U46619.
Biochemical Estimations
Blood collected from the rats in EDTA tubes was immediately
centrifuged, and plasma was separated. Plasma cGMP and cAMP
concentrations were determined by competitive enzyme immunoas-
say with commercial kits (GE Healthcare, Buckinghamshire, UK).
Lactate dehydrogenase activity was estimated with a commercial kit
(Biotrend Chemikalien GmbH, Cologne, Germany), and the thiobar-
bituric acid reactive substances (TBARS) were measured by a
commercial kit (ZeptoMetrix Corp, Buffalo, NY).
Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was isolated from apex of the hearts (including both
infarct and healthy areas) with the RNeasy Fibrous Tissue Mini Kit
(Qiagen, Hilden, Germany). RNA concentration and purity were
determined photometrically (260, 280, and 230 nm). Reverse tran-
scription was performed with the QuantiTect Reverse Transcription
Kit (Qiagen) using 500 g RNA in a volume of 20 L. Quantitative
real-time polymerase chain reactions were performed on the Light-
Cycler480 system with the LightCycler480 Probes Master and
Universal ProbeLibrary probes (Roche, Mannheim, Germany) (see
the online-only Data Supplement).
Histopathological Process
Hearts from rats and canine coronary arterial segments from each
experimental group were fixed in buffered paraformaldehyde solu-
tion (4%) and embedded in paraffin. Then, 5-m-thick sections were
placed on adhesive slides. Rat heart samples were stained with
hematoxylin and eosin; for identification of intracellular cGMP,18
cGMP immunohistochemistry was performed. According to previ-
ously described methods,19 we performed immunohistochemical
staining on coronary arterial rings for nitrotyrosine, and for cGMP.
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end la-
beling (TUNEL) assay was performed to detect DNA strand breaks
(see the online-only Data Supplement).
Chemical Reagents
Cinaciguat (BAY 58 –2667; (4-[((4-carboxybutyl){2-[(4-
phenethylbenzyl)oxy]phenethyl}amino methyl[benzoic]acid) was
provided by Bayer HealthCare (Wuppertal, Germany). For a detailed
description of preparation and application, see the online-only Data
Supplement. Peroxynitrite (Calbiochem, San Diego, Calif) was
diluted with 4.7% NaOH. Custodial was purchased from Dr Franz
Köhler Chemie GmbH (Alsbach-Hähnlein, Germany). Isoproterenol
hydrochloride was dissolved in sterile distilled water; acetylcholine
and sodium nitroprusside, in normal saline; and thromboxane A2-
receptor agonist U46619 (9,11-dideoxy-11,9-epoxy-
methanoprostaglandin F2), in ethanol. These reagents were bought
from Sigma-Aldrich (Steinheim, Germany).
Statistical Analysis
All values were expressed as meanSEM. In the case of canine
hemodynamic parameters, a paired t test was used to compare 2
means within a group (comparison of “before” and “after” values).
Means between the groups were compared by an unpaired 2-sided
Student t test (comparison of the control and cinaciguat groups). In
all other cases, means between groups were compared by 1-way
ANOVA followed by an unpaired t test with Bonferroni correction
for multiple comparisons. Values of P0.05 were considered
significant.
Results
Histopathological Examination of Cardiac Tissues
Compared with the control group (Figure 1A), myocardial
tissues from isoproterenol-treated rats revealed myofibrillar
degeneration, which is related to a dense inflammatory
infiltrate and interstitial edema (Figure 1B). Cinaciguat treat-
ment exhibited a decreased degree of necrosis with less
fragmentation of fibers and inflammation after isoproterenol
administration (Figure 1C). Drug-treated groups showed the
normal appearance of cardiac muscle fibers (Figure 1D).
Table 1 shows the effect of cinaciguat on the degree of
histological changes in myocardial tissues in control and
isoproterenol-induced rats.
Effect of Cinaciguat on Plasma
Lactate Dehydrogenase Activity and
TBARS Concentration
Increased plasma lactate dehydrogenase activity after isopro-
terenol treatment in rats was significantly reduced by ci-
naciguat administration, indicating amelioration of intracel-
lular enzyme release (Figure 2A). Increased plasma TBARS
concentration after isoproterenol treatment was significantly
prevented by cinaciguat treatment, indicating reduced oxida-
tive stress (Figure 2B).
Table 1. Effect of Cinaciguat on the Degree of
Histopathological Changes in Myocardium in the Rat Model of
Isoproterenol-Induced MI
Groups Necrosis Edema Inflammation
Control A A A
Isoproterenol   
Isoproterenolcinaciguat   
Cinaciguat A A A
A indicates no changes; , mild changes; , moderate changes; and
, marked changes.
Figure 1. Histological examinations of myocar-
dium (hematoxylin and eosin staining; magnifi-
cation 100) in each group. Iso indicates
isoproterenol.
Figure 2. Effect of cinaciguat on plasma lactate dehydrogenase
activity (LDH; A) and TBARS (B) in isoproterenol (Iso) -induced
MI in rats. All values are expressed as meanSEM. *P0.05 vs
control; #P0.05 vs isoproterenol.
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Effect of Cinaciguat on Cardiac Function in MI
Compared with the control group, isoproterenol treatment in
rats was associated with significantly decreased systolic
performance. The slope Emax of the end-systolic PV relation-
ship and preload recruitable stroke work showed a marked
reduction in isoproterenol-treated rats. Cinaciguat treatment
resulted in a significant increase in these parameters, indicat-
ing improved LV contractility (Figure 3A and 3B). In
contrast, the end-diastolic PV relationship was increased in
isoproterenol-treated rats, indicating increased end-diastolic
stiffness. Values of the end-diastolic PV relationship of
cinaciguat plus isoproterenol–treated rats did not differ com-
pared with the control group (Figure 3C). Isoproterenol
treatment was associated with impaired cardiac relaxation, as
reflected by prolonged , which was significantly improved
by cinaciguat (Figure 3D). Isoproterenol treatment was asso-
ciated with significantly increased HR and decreased ejection
fraction and stroke volume, which were reversed to the level
of controls after cinaciguat treatment. Isoproterenol treatment
resulted in increased LV end-diastolic pressure, decreased
stroke work and LV systolic pressure, and minimum pressure
development (dP/dt). Cinaciguat had no effect on these
parameters. Rats treated with cinaciguat plus isoproterenol
had lower MAP and LV systolic pressure. Cinaciguat treat-
ment alone had no effect on any of the hemodynamic
parameters studied (Table 2). In the postinfarction cinaciguat
treatment group, we detected significantly improved cardiac
relaxation and a tendency toward improved systolic function
(without reaching the level of statistical significance) com-
pared with the isoproterenol group (Figure 3E through 3H;
see Table I of the online-only Data Supplement).
Effect of Cinaciguat on Mortality in MI
There were no deaths in the control and cinaciguat-treated
groups. The rate of mortality (within 30 minutes) in the
isoproterenol- and cinaciguat plus isoproterenol–treated rats
was 6% and 0%, respectively. During the experimental
period, the mortality rate of rats was 56% for the isoproter-
enol group and 33% for the cinaciguat plus isoproterenol
group (see Table II of the online-only Data Supplement).
Similarly, the mortality rate was markedly reduced after
postinfarction cinaciguat treatment (56% versus 25%) (see
Table III of the online-only Data Supplement).
Effect of Cinaciguat on Plasma cGMP and cAMP
Concentrations and on Myocardial cGMP Level
Significantly increased levels of plasma cGMP were ob-
served in isoproterenol- and cinaciguat plus isoproterenol–
treated rats compared with control and cinaciguat-treated rats
(Figure 4A), whereas plasma cAMP level remained un-
changed (Figure 4B). In the cinaciguat-treated group, the
myocardial cGMP score was significantly higher compared
with the control group (Figure 4C).
Effect of Cinaciguat on Gene Expression
Quantitative real-time polymerase chain reaction from apical
myocardium RNA extracts revealed that mRNA expression
for atrial natriuretic factor (ANF), cyclooxygenase 2 (COX-
2), transforming growth factor-1 (TGF-1), and -actin was
significantly increased in the isoproterenol-treated group
(Figure 5A through 5D), whereas -myosin heavy chain and
endothelial NO synthase mRNA expression remained un-
changed (data not shown). Cinaciguat treatment was shown to
prevent the increase in COX-2, TGF-1, and -actin mRNA
expression in isoproterenol-treated rats, whereas the ANF
mRNA level was not affected.
Effect of Cinaciguat on Cardiac Function After
Global Ischemia/Reperfusion
Table 3 shows the in vivo effects of postischemic cinaciguat
treatment on global cardiac ischemia/reperfusion injury in our
canine model. Baseline values did not differ between groups.
MAP showed a decrease in both groups after ischemia/
Figure 3. Effect of cinaciguat on LV contractility, end-diastolic
stiffness, and cardiac relaxation in isoproterenol (Iso) -induced
MI in rats. A and E, Slope (Emax) of the LV end-systolic PV rela-
tionships; B and F, preload recruitable stroke work (PRSW); C
and G, end-diastolic PV relationship (EDPVR); D and H, time
constant of LV pressure decay (). A through D, Preinfarction
cinaciguat treatment group; E through H, postinfarction
cinaciguat treatment group. All values are expressed as
meanSEM. *P0.05 vs control; #P0.05 vs isoproterenol.
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reperfusion. HR and cardiac output showed no differences
between groups and over time. Coronary blood flow de-
creased significantly in the control group after ischemia/
reperfusion, whereas it remained unchanged in the cinaciguat
group. After ischemia/reperfusion injury, significantly de-
creased contractility (shown by decreased end-systolic PV
relationship and preload recruitable stroke work) was ob-
served in the control group, which was reversed by postis-
chemic cinaciguat treatment.
In Vitro Effects of Cinaciguat on Vascular
Function of Coronary Arterial Rings
Exposed to Peroxynitrite
A marked impairment of endothelial function after exposure
of isolated rings to the reactive oxidant peroxynitrite was
demonstrated in our in vitro organ bath experiments.
Acetylcholine-induced maximal relaxation was significantly
attenuated after exposure of isolated segments to peroxynitrite,
which indicates endothelial dysfunction. Cinaciguat significantly
improved the acetylcholine-induced, endothelium-dependent,
NO-mediated vasorelaxation after exposure of coronary rings
to peroxynitrite (Figure 6A). Endothelium-independent vas-
cular smooth muscle function, indicated by the vasorelaxation
of coronary arteries to sodium nitroprusside, a direct NO donor,
was not impaired by peroxynitrite. Incubation of rings with
peroxynitrite only significantly enhanced the relaxation to 108
mol/L sodium nitroprusside (Figure 6B). Contractile responses
to U46619 did not show any significant differences in the groups
studied (data not shown).
In Vitro Effects of Cinaciguat on cGMP Levels,
Nitro-Oxidative Stress, and DNA Strand Breaks in
Coronary Arterial Rings Exposed to Peroxynitrite
A significantly lower score of cGMP staining (decreased
red staining) was observed in the media of peroxynitrite-
exposed rings compared with control. Cinaciguat treatment
resulted in significantly higher immunoreactivity for
cGMP but did not reach the level of statistical significance
(Figures 7A and 8A).
Increased nitrotyrosine formation observed after exposure
of coronary arteries to peroxynitrite was reduced after ci-
naciguat treatment, as evidenced by decreased brown staining
Table 2. Effect of Cinaciguat on HR, MAP, Maximal LV Pressure, LV End-Diastolic Pressure, Ejection Fraction, Maximum Pressure
Development, Minimum Pressure Development, End-Diastolic Volume, End-Systolic Volume, Stroke Volume, Efficiency, Systemic
Vascular Resistance, Arterial Elastance, Stroke Work, and End-Diastolic PV Relationship in Isoproterenol-Induced MI in Rats
Control Isoproterenol CinaciguatIsoproterenol Cinaciguat
HR, bpm 4279 48512* 44812 41310†
MAP, mm Hg 1023 893 643*† 1157†
LVSP, mm Hg 1334 1023* 884*† 1384†
LVEDP, mm Hg 5.90.3 10.51.0* 9.90.8* 6.10.3†
EF, % 566 414* 464 546
LV dP/dt, mm Hg/s 8372389 7607370 8660548 8426520
LV dP/dt, mm Hg/s 12 063770 6474457* 6608430* 12 087545†
EDV, L 28042 32939 34829 24616
ESV, L 21326 27033 23021 17110†
SV, L 19212 13716* 16515 15512
Efficiency, % 61.84.0 63.04.2 61.33.2 54.04.6
SVR, mm HgmL1min 1.750.22 1.850.17 1.170.22† 1.790.13
Ea, mm Hg/L 0.920.12 1.020.10 0.690.09† 1.070.09
SW, mm Hg L 16 0571172 97111211* 10 3381141* 13 0051345
dP/dt–EDV, mm Hgs1 L1 46.66.4 35.72.9 42.09.9 43.73.4
LVSP indicates maximal LV pressure; LVEDP, LV end-diastolic pressure; EF, ejection fraction; dP/dt, maximum pressure development; dP/dt, minimum pressure
development; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; SVR, systemic vascular resistance; SW, stroke work; and EDPVR, end-diastolic
PV relationship. All values are expressed as meanSEM.
*P0.05 vs control; †P0.05 vs isoproterenol.
Figure 4. Effect of cinaciguat on plasma cGMP (A), plasma
cAMP (B), and myocardial cGMP (C) levels in isoproterenol (Iso)
-induced MI in rats. All values are expressed as meanSEM.
*P0.05 vs control; #P0.05 vs isoproterenol.
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(Figures 7B and 8B). We found pronounced DNA damage in
the wall of peroxynitrite-exposed rings, as reflected by the
quantitative assessment of TUNEL-positive cells. Cinaciguat
treatment tended to decrease peroxynitrite-induced DNA
strand breaks (Figures 7C and 8C).
Discussion
The present study evaluated the effects of cinaciguat, an NO-
and heme-independent sGC activator, on experimentally
induced MI in rats. Our study showed that cinaciguat im-
proves cardiac performance, prevents an increase in oxidative
stress, and ameliorates histopathological changes and intra-
cellular enzyme release in isoproterenol-induced MI. We also
showed that cinaciguat has protective effects on coronary
arteries and enhances endothelium-dependent vasorelaxation
in an in vitro model of vascular nitro-oxidative stress.
Effects of Cinaciguat Pretreatment on Cardiac
Dysfunction in MI
We show that isoproterenol treatment is characterized by
decreased systolic performance accompanied by delayed
relaxation and increased diastolic stiffness of the heart.
Although we found that isoproterenol treatment was associ-
ated with decreased ejection fraction (known to be influenced
by both preload and afterload), it cannot be used reliably to
assess the contractile function in the models in which both
preload and afterload are altered. End-systolic PV relation-
ship (Emax) and preload recruitable stroke work (2 well-
established load-independent contractility indexes)20 were
decreased in isoproterenol-treated rats, suggesting decreased
systolic performance. Another PV-derived index, dP/dt–end-
diastolic volume, which is known to be sensitive to contrac-
tile changes and insensitive to preload, also has a tendency to
be depressed in isoproterenol-treated rats. Impaired ventric-
Figure 5. Effect of cinaciguat on gene expression
in isoproterenol (Iso) -induced MI in rats. ANF (A),
COX-2 (B), TGF-1 (C), and -actin (D) mRNA
expression. All values are expressed as
meanSEM. *P0.05 vs control; #P0.05 vs
isoproterenol.
Table 3. Effect of Postischemic Cinaciguat Treatment on HR, MAP, Cardiac Output, Coronary Blood Flow, End-Systolic PV
Relationship, and Preload Recruitable Stroke Work in the Canine Model of Global Cardiac Ischemia/Reperfusion
Before Ischemia/Reperfusion After Ischemia/Reperfusion
Control Cinaciguat Control Cinaciguat
HR, bpm 1116 1319 12012 1393
MAP, mm Hg 89.23.5 90.12.3 63.04.9† 59.22.8†
CO, L/min 2.990.34 2.650.30 2.390.32 2.750.58
CBF, mL/min 39.635.35 33.833.24 24.002.59† 40.004.13*
ESPVR, mm Hg/mL 5.040.55 6.130.78 2.620.18† 4.270.70*
PRSW, mm Hg 57.693.28 75.1110.39 31.481.88† 59.9812.01*
CO indicates cardiac output; CBF, coronary blood flow; ESPVR, end-systolic PV relation; and PRSW, preload recruitable stroke work. All values are expressed as
meanSEM.
*P0.05 vs control; †P0.05 vs before ischemia/reperfusion.
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ular relaxation (as reflected by the decreased dP/dt, pro-
longed , and increased LV end-diastolic pressure) and
increased end-diastolic stiffness (as reflected by the increased
end-diastolic PV relationship) were also detected in
isoproterenol-treated groups. Relaxation, as an active process,
depends mostly on Ca2 uptake by the sarcoplasmic reticulum
during diastole, and end-diastolic stiffness is affected pre-
dominantly by alterations in myocardial structural compo-
nents. Consistent with diastolic dysfunction, LV end-diastolic
pressure was also increased in this group of rats, which may
be influenced by changes in preload, and its increase may
have resulted from increased venous return. Most of these
parameters return to near-control levels after cinaciguat
treatment, showing improvement in contractile pump func-
tion, LV relaxation, and diastolic stiffness.
Arterial elastance, Ea, directly affects systolic function and
is considered the most reliable index of LV afterload. In rats
with MI, values of Ea were not different from those in the
control group, whereas cinaciguat significantly decreased
afterload. When rats with MI are treated with cinaciguat,
MAP is reduced (and presumably the LV afterload), and the
ventricle can eject blood more rapidly, which increases stroke
volume. After cinaciguat treatment, the ventricle will not fill
to the same end-diastolic volume (preload) found before the
afterload reduction because less blood remains in the ventri-
cle after systole. During MI, stroke volume often falls
because of a depression of LV contractility, resulting in a
compensatory increase in afterload to maintain blood pres-
sure within a physiological range. It has been shown that in
experimental heart failure in dogs, intravenous administration
of cinaciguat resulted in a reduction in cardiac preload and
afterload.21 Deteriorating myocardial status after isoprotere-
nol administration is expected to affect HR. Increased HR
observed in isoproterenol-treated rats, which reduces the time
for diastole filling, can reduce the myocardial blood supply
and cause ischemia. By decreasing afterload through its
vasodilatory effect (shown by decreased MAP in cinaciguat
plus isoproterenol–treated rats), cinaciguat may improve
myocardial oxygen supply and decrease oxygen demand.
Effect of Postischemic Cinaciguat Treatment on
Cardiac Dysfunction in MI
When applying a postinfarction treatment with cinaciguat, we
observed an improvement only in diastolic function; LV
contractility was not significantly ameliorated. In contrast, in
the canine model of reversible global ischemia/reperfusion,
systolic performance after postischemic cinaciguat treatment
was significantly improved. The different results in these
models might be explained by the type of ischemia (irrevers-
ible or reversible) and the timing of the treatment (because of
the repetitive isoproterenol administration, the development
of myocardial necrosis lingers in the rat MI model, so an
exact timing was possible only in the canine model).
Effect of Cinaciguat Pretreatment on Myocardial
Ischemic Tissue Damage
Myocardial tissue damage induced by isoproterenol was
reduced by cinaciguat, as shown by decreased inflammatory
infiltrate, degeneration, and interstitial edema. These data
showed the cardioprotective action of cinaciguat in rats with
MI. The increased activity of the cardiac enzyme lactate
dehydrogenase in the plasma of isoproterenol-treated rats was
Figure 6. Effect of cinaciguat on peroxynitrite
(ONOO) -induced vascular dysfunction in canine
coronary arterial rings. A, Acetylcholine (ACh)
-induced endothelium-dependent vasorelaxation. B,
Sodium nitroprusside (SNP) –induced endothelium-
independent vasorelaxation in each group. Values
represent meanSEM. *P0.05 vs control; #P0.05
vs ONOO.
Figure 7. Representative photomicrographs of
cGMP and nitrotyrosine (NT) immunohistochemis-
try staining and TUNEL assay in the vessel wall of
coronary arterial rings in each group. A, cGMP (red
staining; magnification 400); B, nitrotyrosine
(brown staining; magnification 200); C, TUNEL
(brown staining; magnification 1000). Note the
decreased red and increased brown staining, indi-
cating decreased cGMP immunoreactivity, nitroty-
rosine formation, and DNA damage in the
peroxynitrite-exposed rings.
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decreased by cinaciguat. When myocardial cells are damaged
or destroyed as a result of deficient oxygen supply or glucose,
the cell membrane becomes permeable or may rupture, which
results in the leakage of this enzyme from damaged tissues
into the bloodstream.22 In this study, mRNA expression of
-actin (a cytoskeletal protein important in the maintenance
of cytoarchitecture) was markedly increased by isoproterenol
and significantly downregulated by cinaciguat. These obser-
vations suggest that -actin mRNA expression could be
important in mediating the structural alterations that occur in
the damaged myocardium.
Mechanisms of Cardioprotective Effects of
Cinaciguat Against Ischemic Injury
In animal models of MI, gene expression of ANF is report-
edly upregulated23 and correlates strongly with diastolic wall
stress and stretch.24,25 Our present results on myocardial ANF
mRNA content showed a marked increase in this factor in
isoproterenol- and cinaciguat plus isoproterenol–treated rats,
suggesting end-diastolic wall stress. Recent studies also
showed that production of cGMP by activation of natriuretic
peptides receptor just before therapeutic reperfusion has a
significant anti-infarct effect in both animals26 and humans.27
Our results also showed a correlation between increased
myocardial ANF mRNA expression and plasma cGMP levels
in these groups of rats, which could be a phenomenon that
opposes MI. In heart failure, increased cGMP concentrations
in extracellular fluids, including plasma28 and urine,29 are
believed to result from its passage through the cellular
membrane30 as plasma cGMP is seen as an overspill of
intracellular cGMP. However, plasma cGMP levels do not
necessarily reflect intracellular cGMP levels or the activation
of sGC by intracellular cinaciguat because the overspill from
the intracellular space to the plasma might also be interpreted
as an intracellular overproduction. Any relevant biological
activity of cGMP in plasma remains to be elucidated.
In this study, we observed increased myocardial cGMP
levels in cinaciguat-treated rats. The absence of increased
myocardial cGMP content in cinaciguat plus isoproterenol–
treated rats could be explained by the short half-life of
cinaciguat5 and the relative long interval (17 to 22 hours)
between the last treatment and the experiment. According to
the unchanged cAMP levels, a role for cyclic nucleotide
cross-regulation in the observed cardioprotective effects of
cinaciguat seems rather unlikely.
The cardioprotective effect of the sGC activator could be
mediated by several other mechanisms. Cinaciguat induces
cGMP generation and evokes vasodilation preferentially in
diseased vessels.5 The markedly increased COX-2 mRNA
content in isoproterenol-treated rats was significantly down-
regulated after cinaciguat, suggesting the decrease of proin-
flammatory prostanoid production and ischemic inflamma-
tion. COX-2 is induced only in cardiomyocytes in response to
stress such as ischemia31 and therefore is not expressed in
healthy myocardium. It has been shown that TGF-, a locally
generated cytokine, is upregulated after acute MI in rats and
has a deleterious role in the response of the heart to injury.32
In the present study, increased TGF-1 mRNA content (which
could be due to inflammatory changes) in isoproterenol-
treated rats was significantly downregulated by cinaciguat.
These findings support the concept that cGMP-activated
pathways interfere with TGF- signaling, presumably by
cGMP-mediated inhibition of TGF- expression, as previ-
ously proposed.33
Enormous amounts of reactive oxygen species are pro-
duced during MI and are involved in membrane damage,
leading to increased TBARS levels. We also showed a
significant elevation of plasma TBARS concentration after
isoproterenol that was prevented by cinaciguat, indicating
reduced oxidative stress. It is also known that COX-2 may
generate reactive oxygen species.34 In the present study,
increased COX-2 mRNA content after isoproterenol was
significantly downregulated after cinaciguat, suggesting de-
creased reactive oxygen species generation. In conditions
associated with increased free radical release and oxidative
stress, intracellular cGMP accumulation has been shown to
reduce tissue injury.35
Protective Effect of Cinaciguat on Endothelial
Dysfunction Induced by Peroxynitrite
In coronary arteries exposed to peroxynitrite, we observed
that relaxation to acetylcholine was diminished; in contrast,
sodium nitroprusside–induced relaxation remained un-
changed. Thus, responsiveness of the vascular smooth muscle
cell to NO does not appear to be impaired. Our findings
suggest that the release of NO after activation of muscarinic
receptors in endothelial cells is blunted, whereas the cGMP-
mediated signal transduction system and contractile apparatus
in vascular smooth muscle cells are functionally preserved in
arteries exposed to peroxynitrite. Szabo et al36 also showed
that exposure of isolated vessel rings to high concentrations
of peroxynitrite caused a marked impairment of the endothe-
lium-dependent relaxations. In accordance, our immunohis-
Figure 8. Scoring of cGMP and nitrotyrosine immunohistochem-
istry and TUNEL-assay. Immunohistochemical scores for cGMP
(A) and nitrotyrosine (B) of the coronary artery wall of control,
peroxynitrite-exposed (ONOO; 150 mol/L), and cinaciguat-
treated ONOO-exposed coronary arterial rings. C, Average
number of TUNEL-positive cell nuclei in a microscopic field. Values
represent meanSEM. *P0.05 vs control; #P0.05 vs ONOO.
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tochemical staining for cGMP supports reduced NO bioavail-
ability in coronary arteries exposed to peroxynitrite.
Improvement in endothelial function could be due mainly to
the cytoprotection of endothelium by cinaciguat.
Study Limitations
Supramaximal doses of isoproterenol, a -adrenergic agonist
and well-known inducer of MI,14 are widely used as a model
of evaluating cardioprotective drugs.37 Although this rat
model does not exactly reflect the clinical situation in terms
of coronary occlusion and regional MI, animals develop
“infarct-like” lesions when injected with isoproterenol. In a
rabbit model of coronary artery ligation, Krieg et al38 recently
showed that cinaciguat elicited an infarct-reducing effect. Our
canine model does not reflect acute MI but routine cardiac
surgery with extracorporal circulation and cold cardioplegic
arrest leading to a myocardial and endothelial dysfunction.
Conclusions
The present results indicate that the sGC activator cinaciguat
has a significant effect in the protection of the heart against
MI in rats. Our results show that cinaciguat improves cardiac
function, improves histopathological lesions, reduces oxida-
tive stress, ameliorates intracellular enzyme release, and
decreases COX-2, TGF-1, and -actin mRNA expression in
experimentally induced MI. We also show that cinaciguat
enhances the endothelium-dependent vasorelaxation in ca-
nine coronary arterial rings exposed to peroxynitrite, de-
creases nitro-oxidative stress, and increases intracellular
cGMP levels. Although results of animal experimental stud-
ies should not be directly extrapolated to human biology,
pharmacological sGC activation could be a novel approach
for the prevention and treatment of ischemic heart disease.
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CLINICAL PERSPECTIVE
Although clinical care is improved, public awareness is raised, and health innovations are widely used, myocardial
infarction remains the leading cause of death worldwide. The nitric oxide/soluble guanylate cyclase/cGMP/cGMP–
dependent protein kinase G signaling cascade has been shown to be an important sequence in both preconditioning and
postconditioning. Alteration of this pathway has been thought to be involved in the pathogenesis of various cardiovascular
diseases and is subject to the development of new therapeutic agents. Cinaciguat, the novel nitric oxide– and
heme-independent activator of soluble guanylate cyclase, is currently being evaluated for the treatment of chronic heart
failure in early clinical trials and appears to be well tolerated. Its nitric oxide independence may make it an ideal candidate
for a pharmacological approach in acute myocardial infarction. In this study, we demonstrate that in a rat model of
myocardial infarction induced by isoproterenol, cinaciguat treatment improves histopathological lesions, improves cardiac
performance, improves impaired cardiac relaxation, reduces oxidative stress, and ameliorates intracellular enzyme release.
Furthermore, we demonstrate cardioprotective effect of postischemic cinaciguat treatment in a clinically relevant canine
model of global cardiac ischemia/reperfusion injury. Collectively, these findings make cinaciguat a candidate for the
prevention and treatment of acute myocardial ischemia in humans.
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SUPPLEMENTAL MATERIAL 
 
 
1. Supplemental Methods 
 
 
Hemodynamic measurements  
Rats were anesthetized with sodium pentobarbital (60mg/kg, i.p.), tracheotomized, intubated 
and artificially ventilated. Animals were placed on controlled heating pads, core temperature 
was measured via a rectal probe and was maintained at 37°C. Heart rate (HR), left ventricular 
(LV) systolic pressure (LVPS), LV end-diatolic pressure (LVEDP), mean arterial pressure 
(MAP), maximum pressure development (dP/dtmax) and minimum pressure development 
(dP/dtmin), ejection fraction (EF), stroke volume (SV), end-diatolic volume (EDV), end-
systolic volume (ESV), stroke work (SW), end-diastolic PV relationships (EDPVR) were 
calculated. Ventricular relaxation was assessed by the time constant of LV pressure decay 
(Tau). It has been calculated by the Glantz method (Tau-g; regression of dP/dt versus 
pressure). LV pressure-volume relations were assessed by transiently compressing the inferior 
vena cava. The slope (Emax) of the LV end-systolic PV relationships (ESPVR), preload 
recruitable stroke work (PRSW) and dP/dtmax-EDV as well as efficiency of LV work were 
calculated as load independent indexes of LV contractility.  
At the end of each experiment, 0.1ml hypertonic saline was injected into the jugular vein, and 
from the shift of PV relations parallel conductance volume (Vp) was calculated by the 
software and used for correction for cardiac mass volume. After completing the hemodynamic 
measurements, blood samples were collected from the inferior vena cava for preparation of 
blood plasma for further biochemical measurements. The volume calibration of the 
conductance system was performed as described previously. Briefly, nine cylindrical holes in 
a block 1cm deep and with known diameter ranging from 2 to 11mm were filled with fresh 
heparinized whole rat blood. In this calibration, the linear volume-conductance regression of 
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the absolute volume in each cylinder versus the raw signal acquired by the conductance 
catheter was used as the volume calibration formula.  
 
Canine model of reversible global myocardial ischemia/reperfusion injury  
General management and surgical procedure 
Surgical preparation and general management: The dogs were premedicated with 
propionylpromazine and anesthetized with a bolus of pentobarbital (15mg/kg initial bolus and 
then 0.5mg/kg/h i.v.), paralyzed with pancuronium bromide (0.1mg/kg as a bolus and then 
0.2mg/kg/h i.v.) and endotracheally intubated. The dogs were ventilated with a mixture of 
room air and O2 (FiO2=60%) at a frequency of 12-15/min and a tidal volume starting at 
15ml/kg per minute. The settings were adjusted by maintaining arterial partial carbondioxide 
pressure levels between 35-40mmHg. A urine catheter was inserted through the urethra to 
drain the urinary bladder. The femoral artery and vein were cannulated for recording aortic 
pressure and taking blood samples for the analysis of blood gases, electrolytes and pH, and 
parameters of blood coagulation and inflammation. Basic intravenous volume substitution 
was carried out with Ringer´s solution as necessary. According to the values of potassium, 
bicarbonate and base excess, substitution included administration of potassium chloride and 
sodium bicarbonate (8.4%). Neither catecholamines nor other hormonal or pressor substances 
were administered. Rectal temperature and standard peripheral electrocardiogram were 
monitored continuously. After left anterolateral thoracotomy in the fourth intercostal space, 
pericardiotomy and isolation of the great vessels a perivascular ultrasonic flow probe was 
attached to the ascendent aorta. Aortic pressure was monitored with 5F Millar catheter tip 
manometer (Millar Instruments, Inc., Houston, TX, USA).  
Cardiopulmonary bypass (CPB): After systemic anticoagulation with sodium heparin 
(300U/kg) the left subclavian artery was cannulated for arterial perfusion. The venous cannula 
was placed in the right atrium. The extracorporeal circuit consisted of a heat exchanger, a 
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venous reservoir, a roller pump and a membrane oxygenator primed with Ringer lactate 
solution (1000ml) supplemented with heparin (150U/kg) and 20ml sodium bicarbonate 
(8.4%). Hypothermic CPB was performed for 90min at a lowest temperature of 28°C. After 
initiation of CPB, the hearts were arrested with 1000ml crystalloid cardioplegia (Custodiol®). 
After 60min of cardiac arrest, the aorta was declamped and the heart was reperfused with 
normothermic blood in the bypass circuit. All animals were weaned from CPB without 
inotropic support 20min after the release of the aortic crossclamp. After weaning from CPB, 
heparin was antagonized by protamine iv. over 10min and the animals were monitored for one 
hour. Each animal underwent 60min of cardiac ischemia and 60min of reperfusion. 
Hemodynamic measurements 
Cardiac output (CO) as the equivalent of aortic flow was monitored continuously. The volume 
signal provided by the conductance catheter was registered continuously (Sigma F5, Leycom, 
Leiden, The Netherlands) and computed by the IOX software (EMKA Technologies, France). 
LV pressure-volume loops were constructed on-line. Vena cava occlusions were performed to 
obtain a series of loops for calculation of the slope of the ESPVR. In addition, PRSW was 
calculated as load-independent indices of myocardial contractility. 
Coronary blood flow was measured by an ultrasonic flow meter placed on the left anterior 
descendent coronary artery.  
 
Quantitative real time polymerase chain reaction (PCR). The conditions for PCR were as 
follows: 95°C for 10min (1-cycle), 95°C for 10s, 60°C for 30s (single; 45-cycle 
quantification), 40°C for 10s (1-cycle). Reaction volume was 20µl. Efficiency of the PCR 
reaction was confirmed with standard curve analysis. Sample quantifications were normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression by using a pool of all 
cDNA’s from the control group (positive calibrator). Primers were obtained from TIB 
Molbiol (Berlin, Germany) and their sequences were as follows: atrial natriuretic factor 
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(ANF) forward 5’-CAACACAGATCTGATGGATTTCA-3’; reverse 5’-
CGCTTCATCGGTCTGCTC-3’; cyclooxygenase (COX-2) forward 5’-
CTACACCAGGGCCCTTCC-3’; reverse 5’-TCCAGAACTTCTTTTGAATCAGG-3’; 
transforming growth factor-beta (TGF-β1) forward 5’-TCAGACATTCGGGAAGCAGT-3’; 
reverse 5’-ACGCCAGGAATTGTTGCTAT-3’; β-actin forward 5’-
CTAAGGCCAACCGTGAAAAG-3’; reverse 5’-TACATGGCTGGGGTGTTGA-3’; beta-
myosine heavy chain (β-MHC) forward 5’-GCTGCAGAAGAAGCTCAAAGA-3’; reverse 
5’-GCAGCTTCTCCACCTTGG-3’; endothelial NO synthase (eNOS) forward 5’-
TGACCCTCACCGATACAACA-3’; reverse 5’-CGGGTGTCTAGATCCATGC-3’ and 
GAPDH forward 5’-AGCTGGTCATCAATGGGAAA-3’; reverse 5’-
ATTTGATGTTAGCGGGATCG-3’. Following UPL probes were used: #5 for COX-2 and 
eNOS,  #56 for TGF-β1, #9 for GAPDH, #65 for ANF and β-MHC and #115 for β-actin. 
Evaluation was performed with the Light Cycler 480 SW 1.5 software (Roche, Mannheim, 
Germany). Mean values in the different groups are expressed with the formula: 
 [efficiency]target-(CPsample-CPcalibrator)/[efficiency]reference-(CPsample-CPcalibrator) 
 
Histopathological process 
We performed immunohistochemical staining for cGMP for identification of intracellular 
cGMP content as well as for nitrotyrosine (NT is a product of the nitrating effect of 
peroxynitrite; a marker of nitrosative stress in general, and as “footprint of peroxynitrite” in 
particular 1. TUNEL assay was performed for detection of DNA strand breaks. The detection 
was carried out using a commercial kit following the protocol provided by the manufacturer 
(Chemicon International, Temecula, CA, USA). Rehydrated sections were treated with 
20µg/ml DNase-free Proteinase K (Sigma-Aldrich, Germany) to retrieve antigenic epitopes, 
followed by 3% hydrogen peroxide (H2O2) to quench endogenous peroxidase activity. Free 
3`-OH termini were labeled with digoxigenin-dUTP for 1 hour at 37 ºC utilizing a terminal 
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deoxynucleotidyl transferase reaction mixture (Chemicon International, Temecula, CA, 
USA). Incorporated digoxigenin-conjugated nucleotides were detected using a horseradish 
peroxidase conjugated anti-digoxigenin antibody and 3,3`-diaminobenzidine. Sections were 
counterstained with Gill’s hematoxylin. Dehydrated sections were cleared in xylene, mounted 
with Permount (Fischer Scientific, Germany) and coverslips were applied. Based on the 
intensity and distribution of labelling, semi-quantitative histomorphological assessment was 
performed using conventional microscopy. 
 
Quantification of cGMP-, nitrotyrosine-immunohistochemistry and TUNEL 
A digital camera was used to input microscopic pictures from a low power (100x) 
magnification of the whole section and a high power (400x) examination of four adjacent 
fields. For assessment of TUNEL-labelled cells, the number of positive cell nuclei/ 
microscopic examination field (200x magnification) were counted (four fields characterizing 
each specimen), and an average value was calculated for each experimental group. For cGMP 
and nitrotyrosine staining, after initially evaluating all corresponding tissue sections (x400 
and x200 magnification respectively), the tissue section with the most intense labelling signals 
was used as a reference for maximum labelling intensity. All other tissue sections were 
comparatively evaluated. The colours were measured using densitometry and put in four 
colour classes: one class for background staining and three classes for positively stained areas. 
On the basis of the measured intensity, the colour classes were coupled with score values as 
follows: 0: no positive staining, 1: weak staining, 2: intermediate staining, 3: extensive 
staining. Using the program, we measured the area of the objects in each class in each field, 
assigned an area score (1 = up to 10% positive cells, 2 = 11-50% positive cells, 3 = 51-80% 
positive cells, 4 = >80% positive cells), and calculated an average score for the whole picture 
(intensity score multiplied by area score, 0-12). Finally, each specimen was characterized with 
the average of the 4 adjacent fields. 
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Preparation and application of cinaciguat 
 For in-vivo oral application, cinaciguat was prepared in a suspension in methylcellulose (1%) 
at a volume of 10µl/g and administrated orally at the dose of 10mg/kg and for in-vivo i.v. 
administration, it was dissolved in a 1:1 mixture of Transcutol® and Cremophor®. For in-vitro 
application, cinaciguat was prepared in dimethyl sulfoxide and in a solution of 
glycerol/distilled water/polyethyleneglycol400 (60/100/949=g/g/g). The application and 
dosage of cinaciguat have been determined according to the pharmacokinetic and –dynamic 
properties 2 as well as to the results of previous rodent experiments3. 
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2. Supplemental Tables 
 
Online Table 1: Effect of post-infraction cinaciguat-treatment on heart rate (HR), mean 
arterial pressure (MAP), maximal left ventricular pressure (LVSP), left ventricular end-
diastolic pressure (LVEDP), ejection fraction (EF), maximum pressure development (+dP/dt), 
minimum pressure development (-dP/dt), end-diastolic volume (EDV), end-systolic volume 
(ESV), stroke volume (SV), efficiency, systemic vascular resistance (SVR), arterial elastance 
(Ea), stroke work (SW), end-diastolic pressure-volume relationships (EDPVR) in 
isoproterenol-induced MI in rats. All values are expressed as mean±SEM. *, P<0.05 versus 
control; #, P<0.05 versus isoproterenol. 
 
 Control Isoproterenol Isoproterenol+Cinaciguat Cinaciguat 
HR (beats/min) 427±9 485±12* 494±13 413±10# 
MAP (mmHg) 102±3 89±3 74±4*# 115±7# 
LVSP (mmHg) 133±4 102±3* 92±4*# 138±4# 
LVEDP (mmHg) 5.9±0.3 10.5±1.0* 8.0±1.0*# 6.1±0.3# 
EF (%) 56±6 41±4* 48±6*# 54±6 
LV+dP/dt (mmHg/s) 8372±389 7607±370 8507±403 8426±520 
LV-dP/dt (mmHg/s) 12063±770 6474±457* 6664±308* 12087±545# 
EDV (µl) 280±42 329±39 331±32 246±16 
ESV (µl) 213±26 270±33 298±41 171±10# 
SV (µl) 192±12 137±16* 171±18 155±12 
Efficiency (%) 61.8±4.0 63.0±4.2 53.2±2.3 54.0±4.6 
SVR (mmHg.l-1.min) 1.75±0.22 1.85±0.17 1.09±0.12# 1.79±0.13 
Ea (mmHg/µl) 0.92±0.12 1.02±0.10 0.60±0.04# 1.07±0.09 
SW (mmHg.µl) 16057±1172 9711±1211* 13017±1464 13005±1345 
+dP/dt-EDV (mmHg/s/µl) 46.6± 6.4  35.7±2.9 42.0±9.9 43.7± 3.4 
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Online Table 2: Effect of pre-infarction cinaciguat-treatment on mortality rate in 
isoproterenol-induced MI in rats. 
 Control Isoproterenol Cinaciguat+isoproterenol Cinaciguat
0-30min 
after isoproterenol 
0/7 
(0%) 
1/18  
(6%) 
0/15 
(0%) 
0/9 
(0%) 
30min-24h 
after isoproterenol 
0/7 
(0%) 
9/18 
(50%) 
5/15 
(33%) 
0/9 
(0%) 
Cumulative 0/7 
(0%) 
10/18 
(56%) 
5/15 
(33%) 
0/9 
(0%) 
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Online Table 3: Effect of post-infraction cinaciguat-treatment on mortality rate in 
isoproterenol-induced MI in rats. 
 
 
 Control Isoproterenol Cinaciguat+Isoproterenol Cinaciguat 
0-30min 
after isoproterenol 
0 
(0%) 
1/18 
(6%) 
0/36 
(0%) 
0 
(0%) 
30min-24h 
after isoproterenol 
0 
(0%) 
9/18 
(50%) 
9/36 
(25%) 
0 
(0%) 
Cumulative 0 
(0%) 
10/18 
(56%) 
9/36 
(25%) 
0 
(0%) 
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